Today’s AI Top Pick: PSIX

10/2/2026 · Highly Shorted Deep Rotation RSI & Conf screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

The desk streams live daily· see the schedule →

Measured daily model accuracy · PSIX82%462 resolved forecasts · 45d window · verify →

Today's pick · Highly Shorted Deep Rotation RSI & ConfPSIXBUY NOW14.8 / 1010/2/2026

PSIX (Power Solutions International) is the best risk/reward entry in this pool because it is the only name that combines the strongest fundamentals, the highest forecast magnitude, and clean multi-timeframe confirmation. On the tape, all three timeframes agree: the 1d forecast cluster sits at fc_mid 45.84% / fc_long 34.32% with price at 86.14% of its 21-bar range (not chasing, only -3.14% off the high), while the 4h cluster is at fc_mid 77.14% and the 1wk fc_mid is -36.30% with price at 94.59% of range — a deep, low-positioning base with a large upside forecast. Kronos near_term_bullish is 1.0 and bullish_prob is 1.0, well above the 0.55 meaningful threshold. Fundamentally it is the clear leader: PE 15.43, fwdPE just 11.63, PEG 1.98, ROE 40.07%, profit margin 10.03%, operating margin 13%, sales YoY +13.17%, and a strong analyst consensus (recom 1 = Strong Buy) with +53.7% target upside. Critically, the headline landmine check passes: on 2026-09-30 the company secured a $220M committed revolving credit facility — a concrete, positive catalyst that de-risks balance-sheet funding for growth rather than signaling distress. Short float of 21% provides the squeeze fuel the screen is built around. Unlike KULR (dilution pause, -607% margin) or INO (binary FDA event, -100% sales), PSIX is a profitable, funded, cheap short-squeeze rotation with no negative catalyst undercutting the thesis. TODAY is the right entry because the setup is confirmed across all timeframes at low range positions with a fresh funding catalyst — waiting risks a gap-up on the credit facility news and short squeeze.

Entry zone

Buy on dips to $43.50-$45.60 (current ~$45.40-45.62); accumulate in this band rather than chasing above $46

Stop loss

Close below $41.50 (roughly -9% and below the 21-bar support cluster)

First target

$52.00 (near-term re-rating toward analyst target zone)

Longer target

$62.00 (swing target near +53.7% analyst upside / squeeze extension)

Risks

Small-cap ($1.05B) with high single-customer/segment concentration; earnings can gap sharply
Short float of 21% is a double-edged sword — a failed squeeze can accelerate short-seller pressure
PEG of 1.98 implies growth is already priced in; any miss on the +13% sales trend pressures the multiple
YTD performance -20.55% and -50.76% over the year show an extended downtrend that could re-test lows
Cyclical industrial exposure — a demand slowdown would compress the 13% operating margin

Honorable mentions

MNROStrong #2: 31.05% short float (highest in the list), 1d at 97.9% of range with fc_mid 13.21% and fc_long 15.08%, near_term_bullish 0.8. Thesis slightly undercut by 'Strategic Sale' ambiguity and a 'Hold' consensus, so BUY_PULLBACK below $14.00 rather than chase at 98% of range.

INOHigh-conviction speculative #3: 19.34% short float, fc_long 23.93% on 1d, +162% target upside, and a binary Oct 30 FDA PDUFA catalyst on INO-3107. Negative margins and -100% sales make this a news-driven momentum play, not a fundamentals buy — BUY_PULLBACK with tight risk.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	PSIX	BUY NOW	14.8	Cheap, profitable, funded short-squeeze with full multi-timeframe confirmation and a fresh $220M credit facility catalyst.
2	MNRO	BUY PULLBACK	9.0	Highest short float (31%) and strong 1d forecast, but strategic-sale ambiguity and 98%-of-range positioning argue for a dip entry.
3	KULR	BUY PULLBACK	9.8	Drone-dominance orders are a positive catalyst, but -607% margin and dilution pause make this a tighter-risk speculative play.
4	INO	BUY PULLBACK	9.5	Binary Oct 30 FDA catalyst with +162% upside, but negative margins and -100% sales demand tight risk management.
5	TSSI	WAIT	11.8	Strong 1d forecast cluster but only one timeframe available and -26.5% sales growth limits conviction.
6	XPOF	BUY PULLBACK	7.8	30.43% short float and positive gross margin, but guidance cut and UBS PT cut to $4.5 undercut the thesis.
7	SMMT	WAIT	8.2	Barcales raised PT to $20 but Equal-Weight keeps it a trade, not a conviction buy.
8	SERV	BUY PULLBACK	8.0	40.13% short float and Beacon narrative are exciting, but -2447% operating margin is a high-risk momentum setup.
9	BTBT	WAIT	7.5	Crypto-correlated with fair-value debate headwind; wait for clearer trend confirmation.
10	SES	WAIT	7.5	Highest fc_long (211%) but RSI 75 overbought and -289% margin argue for a pullback entry.
11	BLSH	WAIT	7.3	Blockchain.com IPO story is a catalyst, but KBW PT cut and -390% margin limit near-term conviction.
12	DXC	WAIT	6.8	Cheap at fwdPE 3.94 but 'Reduce' analyst consensus caps upside.
13	RR	BUY PULLBACK	6.8	Moderate Buy consensus with full timeframe agreement, but -465% operating margin is a speculative entry.
14	SYM	WAIT	6.7	Massive fc_long (21%) but PE 478 and near_term_bullish only 0.4 make this a pullback-only name.
15	SEI	WAIT	6.5	Strong fundamentals and +68% performance but bullish_prob 0 and -46% expected return signal caution.
16	CDZI	BUY PULLBACK	6.3	Dividend added and full timeframe agreement, but -353% margin and 25.69 debt/equity are serious red flags.
17	PRGO	WAIT	6.3	Cheap at fwdPE 5.84 but -41% margin and only 0.2 bullish_prob limit appeal.
18	ARQQ	WAIT	6.2	350% sales growth is real but -4715% margin and bullish_prob 0 make it a wait.
19	GEMI	WAIT	6.0	Gemini/crypto narrative is intriguing but -320% margin and no bullish signal argue for patience.
20	STAA	BUY PULLBACK	5.8	Recovery story with Overweight upgrade, but PE 336 and -23% 4h drawdown need a cleaner entry.
21	TDC	WAIT	5.5	Cheap at PE 6.3 but COO dumped shares and bullish_prob 0 limit near-term appeal.
22	AMKR	WAIT	5.5	Solid semis name but bullish_prob 0 and -41% expected return signal a pullback.
23	OMER	WAIT	5.3	Overweight upgrade with +98% upside but -189% margin and bullish_prob 0 are caution flags.
24	UPXI	WAIT	5.2	Overweight maintained but -984% margin and only 0.2 near_term_bullish limit appeal.
25	GO	WAIT	5.0	BofA upgrade to Buy is positive but -8% margin and bullish_prob 0 argue for a pullback.
26	RXRX	WAIT	5.0	AI-drug narrative with 37% short float but -945% margin and bullish_prob 0 limit near-term appeal.
27	CEPT	WAIT	4.5	48.8% short float is the highest in the list but stale data (Jul 18) and no forecast block warrant a wait.
28	BIRD	BUY PULLBACK	4.5	$450M funding is a catalyst and 1d at 100% of range with fc_long 49%, but near_term_bullish 0 needs a dip.
29	CRDF	BUY PULLBACK	4.3	Buy upgrade with +335% upside but -7888% margin and -5.38 epsNextY are high-risk speculative.
30	DUOL	AVOID	10.8	Premium valuation (PE 17.58, PS 5.99) and bullish_prob 0 despite strong margins make this a hold/avoid.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord